Evidence map›Paper›PMID 27650937›Full record

ArticleJournal of endourology2016

Repeat Robotic Partial Nephrectomy: Characteristics, Complications, and Renal Functional Outcomes.

Matthew J Watson, Abhinav Sidana, Annerleim Walton Diaz, M Minhaj Siddiqui, Ryan A Hankins, Gennady Bratslavsky, W Marston Linehan, Adam R Metwalli

Open access · greenAbstract read
In one paragraph

Article in Journal of endourology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Feasibility and Safety of Repeat Robot-Assisted Partial Nephrectomy for Ipsilateral Local Recurrence: A Case Series.International journal of urology : official journal of the Japanese Urological Association · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. How far has robot-assisted partial nephrectomy reached?Investigative and clinical urology · 2023
    Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Metachronous renal cell carcinoma: an unbeatable leviathan?Annals of translational medicine · 2019
    Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Matthew J Watson1 Urologic Oncology Branch, National Cancer Institute, National Institutes of Health , Bethesda, Maryland.
Abhinav Sidana1 Urologic Oncology Branch, National Cancer Institute, National Institutes of Health , Bethesda, Maryland.
Annerleim Walton Diaz1 Urologic Oncology Branch, National Cancer Institute, National Institutes of Health , Bethesda, Maryland.
M Minhaj Siddiqui2 Department of Urology, University of Maryland , Baltimore, Maryland.
Ryan A Hankins3 Department of Urology, Georgetown University Hospital , Washington, District of Columbia.
Gennady Bratslavsky4 Department of Urology, Upstate Medical University , Syracuse, New York.
W Marston Linehan1 Urologic Oncology Branch, National Cancer Institute, National Institutes of Health , Bethesda, Maryland.
Adam R Metwalli1 Urologic Oncology Branch, National Cancer Institute, National Institutes of Health , Bethesda, Maryland.
National Institutes of Health · USGeorgetown University · USSUNY Upstate Medical University · USUniversity of Maryland, Baltimore · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMultifocal and hereditary kidney cancers often require repeated ipsilateral nephron sparing procedures with higher blood loss and complication rates compared to first time renal surgery. Consequently, many surgeons avoid minimally invasive techniques in the setting. We present the characteristics, complications, and short-term renal functional outcomes of patients who underwent a repeat robotic partial nephrectomy (rRPNx). MATERIALS AND

methodsA database was retrospectively reviewed to identify patients who underwent robotic partial nephrectomies between January 2007 and December 2013. Selection criteria for the rRPNx cohort included patients who had undergone at least two ipsilateral renal surgeries, with the second procedure being an rRPNx. All other patients comprised the initial robotic partial nephrectomy (iRPNx) group.

resultsOne hundred twenty-four patients who underwent robotic partial nephrectomy during the study period were identified. rRPNx constituted 26 (21%) of the total cases. Age of the rRPNx cohort was similar (p = 0.56), but number of tumors resected was two-fold greater in the rRPNx group (p = 0.44). Neither surgery time nor renal clamp time was significantly longer in either group (p = 0.18 and p = 0.65, respectively). Importantly, estimated blood loss (EBL) was significantly larger than in the iRPNx group (p = 0.01). Both groups had similar intravenous pain medication administration durations (p = 0.32), but postsurgical length of stay was greater for the rRPNx patients (p = 0.011). There were no significant differences in clavian complication rates (p = 0.17-0.39), with the exception of urine leak which occurred more frequently in the rRPNx group (p = 0.01). There was no difference in percent change in serum creatinine or estimated glomerular filtration rate (p = 0.89 and p = 0.67, respectively).

conclusionsrRPNx is safe and feasible in select patients. EBL, postoperative lengths of stay, and urine leak were the only factors significantly associated with rRPNx compared to iRPNx. Patient 3-month follow-up revealed excellent and comparable outcomes between the two groups.

Indexed as

AdultCreatinineDatabases, FactualFemaleGlomerular Filtration RateHumansKidneyKidney Function TestsKidney NeoplasmsLength of StayMaleMiddle AgedNephrectomyNephronsOperative TimePatient SelectionCreatininelaparoscopy approachrenal cancerrobotics

Identifiers

PMID27650937
PMCPMC5107716
OpenAlexW2523401995

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.